Monument Therapeutics

Monument Therapeutics is an independent UK-based biotechnology company founded in 2019 as a spin-out from Cambridge Cognition. The company focuses on bringing precision medicine to neuroscience drug development, targeting serious diseases of the central nervous system. Their approach involves the use of proprietary digital biomarkers to reduce heterogeneity and identify patients with homogenous underlying neurobiology, aligning them with appropriately targeted compounds. This strategy parallels the successful use of biomarkers in cancer treatment. Monument Therapeutics aims to apply digital biomarkers to neuroscience drug development, particularly in clinical areas with high unmet needs. The company recently secured £2.63M in a Seed Round investment on 01 July 2021 from noteworthy investors including Neo Kuma Ventures, GM&C Life Sciences Fund, Wren Capital LLP, and O2h Ventures. This injection of capital underscores the growing interest in precision medicine and the potential of Monument Therapeutics' approach. As the company continues to make strides in bringing innovative solutions to the biotechnology, health care, and pharmaceutical industries from their headquarters in the United Kingdom, they present an intriguing prospect for venture capitalists looking to invest in cutting-edge precision medicine technologies.